Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2010

Open Access 01-03-2010

Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men

Authors: Ina U. Park, Joel M. Palefsky

Published in: Current Infectious Disease Reports | Issue 2/2010

Login to get access

Abstract

The incidence of human papillomavirus (HPV)–associated anal cancer in men who have sex with men (MSM) is striking and has not been mitigated by the use of highly active antiretroviral therapy. Detection and treatment of high-grade anal intraepithelial neoplasia (HGAIN) may reduce the incidence of anal cancer. Anal cytology is a useful tool to detect HGAIN; annual screening of HIV-positive MSM and biennial screening of HIV-negative MSM appears to be cost-effective. MSM with abnormal cytology should be referred for high-resolution anoscopy and biopsy. Individuals with HGAIN should receive treatment; treatment modalities for HGAIN demonstrate moderate efficacy and are usually well tolerated, but greater study is required to determine which treatment is optimal. Large prospective studies are needed to document the efficacy of screening and treatment of HGAIN on anal cancer incidence. The HPV vaccine holds promise for primary prevention of anal cancer in MSM, but significant implementation challenges remain.
Literature
1.
•• Piketty C, Selinger-Leneman H, Grabar S, et al.: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008, 22:1203–1211. The incidence of anal cancer was 75 per 100,000 person-years among HIV-positive MSM in the French Hospital Database on HIV and increased from the pre-HAART era to the post-HAART era.CrossRefPubMed
2.
•• Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120–1130. Linking AIDS and cancer registry data from 15 US states, this study showed the incidence of anal cancer increased 104% from the pre-HAART era to the post-HAART era (20.7 cases vs 42.3 cases /100,000 person-years).CrossRefPubMed
3.
•• D’Souza G, Wiley DJ, Li X, et al.: Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008, 48:491–499. The incidence of anal cancer in the US multicenter AIDS cohort study was 137/100,000 person-years among HIV-positive MSM since 1996.CrossRefPubMed
4.
•• Patel P, Hanson DL, Sullivan PS, et al.: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008, 148:728–736. Matching data from the Adult and Adolescent Spectrum of HIV Disease Project, the HIV Outpatient Study and the Surveillence, Epidemiology, and End Results Program, this study showed that the incidence of anal cancer in HIV-positive MSM was 78 per 100,000 person-years since 2000.PubMed
5.
Joseph DA, Miller JW, Wu X, et al.: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008, 113(10 Suppl):2892–2900.PubMed
6.
Daling JR, Weiss NS, Hislop TG, et al.: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987, 317:973–977.PubMedCrossRef
7.
• Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124:2375–2383. This meta-analysis describes the prevalence and type distribution of HPV in 992 cases of invasive anal cancer—472 HSIL cases and 360 LSIL cases. HPV prevalence was 71%, 91%, and 88%, respectively. HPV 16 or HPV 18 were present in 72% of anal cancers.CrossRefPubMed
8.
Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14–19.PubMed
9.
Chin-Hong PV, Vittinghoff E, Cranston RD, et al.: Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004, 190:2070–2076.CrossRefPubMed
10.
Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998, 177:361–367.CrossRefPubMed
11.
•• Chin-Hong PV, Berry JM, Cheng SC, et al.: Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med 2008, 149: 300–306. This population-based study of HIV-positive and HIV-negative MSM in San Francisco, California demonstrated that the prevalence of HGAIN was 43% in HIV-positive and 25% in HIV-negative MSM. Self-collected anal cytology demonstrated similar sensitivity for detection of AIN compared with clinician-collected samples.PubMed
12.
Palefsky JM, Holly EA, Ralston ML, et al.: High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998, 12:495–503.CrossRefPubMed
13.
Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005, 19:1407–1414.CrossRefPubMed
14.
Devaraj B, Cosman BC: Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum 2006, 49:36–40.CrossRefPubMed
15.
Watson AJ, Smith BB, Whitehead MR, et al.: Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 2006, 76:715–717.CrossRefPubMed
16.
Scholefield JH, Castle MT, Watson NF: Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 2005, 92:1133–1136.CrossRefPubMed
17.
Palefsky JM, Holly EA, Ralston ML, et al.: Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001, 28:422–428.PubMed
18.
Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187–194.CrossRefPubMed
19.
van der Helm JJ, Hoebe CJ, van Rooijen MS, et al.: High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis 2009, 36:493–497.CrossRefPubMed
20.
Cranston RD, Darragh TM, Holly EA, et al.: Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men. J Acquir Immune Defic Syndr 2004, 36:915–920.CrossRefPubMed
21.
Darragh TM, Jay N, Tupkelewicz BA, et al.: Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Acta Cytologica 1997, 41:1167–1170.PubMed
22.
Solomon D, Davey D, Kurman R, et al.: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114–2119.CrossRefPubMed
23.
Panther LA, Wagner K, Proper J, et al.: High-resolution anoscopy findings for men who have sex with men: inaccuracy of anal cytology as a predictor of histologic high-grade anal intraepithelial neoplasia and the impact of HIV serostatus. Clin Infect Dis 2004, 38:1490–1492.CrossRefPubMed
24.
Chiao EY, Giordano TP, Palefsky JM, et al.: Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006, 43:223–233.CrossRefPubMed
25.
• Berry JM, Palefsky JM, Jay N, et al.: Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009, 52:239–247. This study describes the sensitivity of abnormal anal cytology to detect HGAIN. Sensitivity was 87% in HIV-positive men and 55% in HIV-negative men.PubMed
26.
Palefsky JM, Holly EA, Hogeboom CJ, et al.: Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:415–422.PubMed
27.
Goldstone SE, Enyinna CS, Davis TW: Detection of oncogenic human papillomavirus and other predictors of anal high-grade dysplasia in men who have sex with men with abnormal cytology. Dis Colon Rectum 2009, 52:31–39.PubMed
28.
•• Kaplan JE, Benson C, Holmes KH, et al.: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58(RR-4):1–207. This article presents the guidelines from the US Public Health Service for screening and treatment of AIN in HIV-positive individuals.
29.
Goldie SJ, Kuntz KM, Weinstein MC, et al.: The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999, 281:1822–1829.CrossRefPubMed
30.
Goldie SJ, Kuntz KM, Weinstein MC, et al.: Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000, 108:634–641.CrossRefPubMed
31.
Karnon J, Jones R, Czoski-Murray C, Smith KJ: Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health (Oxf) 2008, 30:293–304.CrossRef
32.
Jay N, Berry JM, Darragh T, .Palefsky JM: Abstract P19.16: Treatment of diffuse high-grade anal intraepithelial neoplasia with 5% fluorouracil cream. Presented at the 25th International Papillomavirus Conference. Malmo, Sweden; 2009.
33.
•• Pineda CE, Berry JM, Jay N, et al.: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum 2008, 51:829–835. This article describes a retrospective study of patients treated for HGAIN using surgery guided by HRA, followed by office-based procedures to treat recurrent disease. After 36 months of follow-up, HGAIN had a high resolution rate (86%) with a low complication rate.CrossRefPubMed
34.
• Singh JC, Kuohung V, Palefsky JM: Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men. J Acquir Immune Defic Syndr 2009, 52:474–479. This retrospective study of 35 HIV-positive and 19 HIV-negative MSM demonstrated efficacy of 85% trichloroacetic acid in the treatment of AIN. On a per lesion basis, 71% of HGAIN lesions cleared to either LGAIN or no lesion; in HIV-positive MSM, those with two or fewer lesions had the highest rate of clearance.PubMed
35.
Wieland U, Brockmeyer NH, Weissenborn SJ, et al.: Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006, 142:1438–44.CrossRefPubMed
36.
• Kreuter A, Potthoff A, Brockmeyer NH, et al.: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol 2008, 128:2078–83. This open label-study of 17 patients treated with imiquimod for AIN demonstrated a 74% clearance of the original lesion; however, more than half of patients developed new lesions during follow-up.CrossRefPubMed
37.
Goldstone SE, Hundert JS, Huyett JW: Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum 2007, 50:565–75.CrossRefPubMed
38.
• Stier EA, Goldstone SE, Berry JM, et al.: Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. J Acquir Immune Defic Syndr 2008, 47:56–61. This small, multicenter, phase 1 study demonstrated that infrared coagulator treatment of HGAIN in HIV-positive individuals was well tolerated, with resolution of 64% of lesions after treatment.CrossRefPubMed
39.
Cranston RD, Hirschowitz SL, Cortina G, Moe AA: A retrospective clinical study of the treatment of high-grade anal dysplasia by infrared coagulation in a population of HIV-positive men who have sex with men. Int J STD AIDS 2008, 19:118–120.CrossRefPubMed
40.
Nathan M, Hickey N, Mayuranathan L, Vowler SL, Singh N: Treatment of anal human papillomavirus-associated disease: a long term outcome study. Int J STD AIDS 2008, 19:445–9.CrossRefPubMed
41.
Guiliano A, Palefsky J: Abstract O-01.07: Quadrivalent HPV Vaccine Efficacy Against Male Genital Disease And Infection. 25th International Papillomavirus Conference. Malmo, Sweden, 2009.
42.
Ault KA: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861–8.CrossRefPubMed
43.
Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.CrossRefPubMed
44.
Centers for Disease Control and Prevention: National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:997–1001.
45.
• Chin-Hong PV, Husnik M, Cranston RD, et al.: Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009, 23: 1135–42. This prospective cohort study of HIV-negative MSM demonstrated that infection with two or more types of anal HPV was independently associated with acquisition of HIV after adjustment for demographic and other risk factors.CrossRefPubMed
46.
Sexton J, Garnett G, Rottingen JA: Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005, 32:351–7.CrossRefPubMed
Metadata
Title
Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men
Authors
Ina U. Park
Joel M. Palefsky
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 2/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0090-7

Other articles of this Issue 2/2010

Current Infectious Disease Reports 2/2010 Go to the issue

Clinical Trial Report

The Next Era of HCV Antiviral Therapy Finally Begins: Part 2

ReviewPaper

Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men

ReviewPaper

β-Lactamase–Producing Bacteria in Upper Respiratory Tract Infections

ReviewPaper

Partner Concurrency and the STD/HIV Epidemic

ReviewPaper

The Role of Adenovirus in Respiratory Tract Infections

ReviewPaper

Recent Advances in the Understanding and Management of Kawasaki Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits